Skip to main content
. 2013 Aug 21;8(8):e74676. doi: 10.1371/journal.pone.0074676

Figure 5. Jak inhibition affects macrophages alternative activation by HDL.

Figure 5

BMDM were pre-treated for 2h with Jak pharmacological inhibitors (hatched bars. Ruxolitinib/Jak1/2 inhibitor: 1μM. TG101348/Jak2 inhibitor: 1μM: Kaempferol/Jak3 inhibitor: 40μM) or vehicle (black bars), and then treated for 6h with HDL (50μg/mL) or IL-4 (10ng/mL). Arg-1 (A, C, E) and Fizz-1 (B, D, F) expression are presented as the percentage of activation compared to non-inhibited conditions. The induction of Arg-1 and Fizz-1 by HDL was ~2X for each, and for IL-4 was >300 for Arg-1 and Fizz-1 and these values were set to 100%. Results are representative of three independent experiments. Asterisks indicate statistically significant differences compared to the vehicle-treated conditions (*p<0.05, **p<0.01, ***p<0.001).